✦ LIBER ✦

Biomarkers of myocardial injury as surrogate end-points for remote ischemic conditioning trials

✍ Scribed by Efstathios K. Iliodromitis; Dimitrios Farmakis; Dimitrios T. Kremastinos

Book ID: 116549959
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 50 KB
Volume: 149
Category: Article
ISSN: 0167-5273
DOI: 10.1016/j.ijcard.2011.02.067

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Definitions of Periprocedural Myocardial

Definitions of Periprocedural Myocardial Infarction as Surrogates for Catheterization Laboratory Quality or Clinical Trial End Points

✍ Baker, Nevin C.; Lipinski, Michael J.; Escarcega, Ricardo O.; Magalhaes, Marco A 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 453 KB

Protein C as a surrogate end-point for c

Protein C as a surrogate end-point for clinical trials of sepsis

✍ Kathleen D Liu,Michael A Matthay 📂 Article 📅 2008 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 39 KB

Assessment of DNA flow cytometry as a su

Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial

✍ Silvia Bruno; Rosalba Torrisi; Massimo Costantini; Laura Baglietto; Vincenzo Fon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

Although conventional cytology represents the most widely performed cytometric analysis of bladder cancer cells, DNA flow cytometry has, over the past decade, been increasingly used to evaluate cell proliferation and DNA ploidy in cells from bladder washings. We have investigated whether DNA flow cy

CURRENT DEFINITIONS OF PERIPROCEDURAL MY

CURRENT DEFINITIONS OF PERIPROCEDURAL MYOCARDIAL INFARCTION ARE NOT SURROGATE MARKERS FOR CATHETERIZATION LAB QUALITY OR CLINICAL TRIAL END POINTS

✍ Baker, Nevin; Alarcon, Ricardo Escarcega; Lipinski, Michael; Minha, Sa'ar; Perei 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Estimated GFR Decline as a Surrogate End

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

✍ Lambers Heerspink, Hiddo J.; Weldegiorgis, Misghina; Inker, Lesley A.; Gansevoor 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 630 KB